'Teicoplanin' FDA approved was found to be more effective against COVID-19: IIT Delhi study

-By KI News Team | Sept. 30, 2020, 8:19 p.m.

The research by the Indian Institute of Technology (IIT) has found a potential therapeutic drug against COVID-19. The FDA approved clinical drug “Teicoplanin” is showing positive leads against the coronavirus according to the research done by Kusuma School of Biological Science. They concluded the result by doing a research where they screened an assemblage of 23 approved drugs.

Teicoplanin is an FDA-approved antibiotic glycopeptide that is widely used to treat human Gram-positive bacterial infections with a low toxicity profile. Currently, the Sapienza University at Rome has been carrying out a clinical study with drug Teichoplanin. Dr Patel states that the clinical investigation to conclude the explicit role of Teicoplanin against the novel coronavirus requires a detailed study on a large cohort, in different stages with the mild, moderate and critically ill patients.

The research studied an array of 23 approved drugs for therapeutic options for those having an inhibitory impact towards the main protease of the virus 3CLPro and Teicoplanin demonstrated the most encouraging restraint of the proteolytic movement of this primary viral protease.

Dr Ashok Patel, Professor at IIT Delhi did a study assisted by Dr Pradeep Sharma from AIIMS where the Teicoplanin was shown more effective compared to the other important and chief drugs used against SARS-CoV-2, such as Lopinavir and Hydroxychloroquine. The research was also published in the International Journal of Biological Macromolecules.